4D Molecular Therapeutics (NASDAQ:FDMT) and VectivBio (NASDAQ:VECT) Critical Survey

4D Molecular Therapeutics (NASDAQ:FDMT) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and VectivBio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$20.72 million	20.12	-$100.84 million	($2.30)	-3.49
VectivBio	$27.34 million	N/A	-$93.74 million	N/A	N/A

VectivBio has higher revenue and earnings than 4D Molecular Therapeutics.

Insider and Institutional Ownership

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.3% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares 4D Molecular Therapeutics and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	N/A	-24.06%	-22.52%
VectivBio	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings for 4D Molecular Therapeutics and VectivBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	0	1	8	0	2.89
VectivBio	0	0	0	0	0.00

4D Molecular Therapeutics presently has a consensus target price of $47.00, suggesting a potential upside of 486.03%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than VectivBio.

Summary

VectivBio beats 4D Molecular Therapeutics on 5 of the 9 factors compared between the two stocks.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.